TY - JOUR
T1 - Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic pneumonia among children in rural Bangladesh
T2 - A case-control study
AU - for the Projahnmo Study Group in Bangladesh
AU - McCollum, Eric D.
AU - Ahmed, Salahuddin
AU - Roy, Arun D.
AU - Chowdhury, Nabidul H.
AU - Schuh, Holly B.
AU - Rizvi, Syed J.R.
AU - Hanif, Abu A.M.
AU - Khan, Ahad M.
AU - Mahmud, Arif
AU - Pervaiz, Farhan
AU - Harrison, Meagan
AU - Reller, Megan E.
AU - Simmons, Nicole
AU - Quaiyum, Abdul
AU - Begum, Nazma
AU - Santosham, Mathuram
AU - Checkley, William
AU - Moulton, Lawrence H.
AU - Baqui, Abdullah H.
N1 - Funding Information:
This study is funded by the Bill & Melinda Gates Foundation [ OPP1084286 , OPP1117483 ] and GlaxoSmithKline [ 90063241 ]. EDM was also supported by the Fogarty International Center of the National Institutes of Health under Award Number K01TW009988 for the research reported in this publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Bill & Melinda Gates Foundation, GlaxoSmithKline or the National Institutes of Health.
Funding Information:
We thank the children and caregivers for participating in this study. We also thank the Projahnmo Study Group field and data management staff, the Ministry of Health and Family Welfare, Government of Bangladesh, GlaxoSmithKline, and the Bill and Melinda Gates Foundation their support of this study. Funding acquisition: AHB. Conceptualization and design: EDM, NS, MS, WC, LHM and AHB. Data curation: EDM, NHC, SJR, NB and AHB. Data collection: EDM, SA, AMK, AAH, AM, and ADR. Data analysis: EDM, NHC, SJR, HBS, NS and LHM. Data interpretation: EDM, SA, NS, MER, MH, HBS, MS, LHM, WC and AHB. Writing?original draft: EDM. Writing?review & editing: EDM, SA, NHC, SJR, AMK, ADR, AAMH, FP, NS, MER, MH, HBS, AQ, NB, MS, LHM, WC, and AHB. This study is funded by the Bill & Melinda Gates Foundation [OPP1084286, OPP1117483] and GlaxoSmithKline [90063241]. EDM was also supported by the Fogarty International Center of the National Institutes of Health under Award Number K01TW009988 for the research reported in this publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Bill & Melinda Gates Foundation, GlaxoSmithKline or the National Institutes of Health. The funders had no role in the design, implementation, analyses, interpretation, write up, or decision to publish. The Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine, Bangladesh Institute of Child Health, and the Ethical Review Committee of the International Centre for Diarrhoeal Diseases Research, Bangladesh, Institutional Review Boards all approved the study's protocol.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/9/29
Y1 - 2020/9/29
N2 - Background: Pneumococcal conjugate vaccine (PCV) effectiveness against radiographic pneumonia in South Asia is unknown. Bangladesh introduced PCV10 in 2015 using a three dose primary series (3 + 0). We sought to measure PCV10 effectiveness for two or more vaccine doses on radiographic pneumonia among vaccine-eligible children in rural Bangladesh. Methods: We conducted a matched case-control study over two years from 2015 to 2017 using clinic and community controls in three subdistricts of Sylhet, Bangladesh. Cases were vaccine eligible 3–35 month olds at Upazila Health Complex outpatient clinics with World Health Organization-defined radiographic primary endpoint pneumonia (radiographic pneumonia). Clinic controls were matched to cases within a one week time window by age, sex, and clinic and had an illness unlikely to be Streptococcus pneumoniae; community controls were healthy and similarly matched within a one week time window by age and sex, and distance from the clinic. We estimated adjusted vaccine effectiveness (aVE) using conditional logistic regression. Results: We matched 1262 cases with 2707 clinic and 2461 community controls. Overall, aVE using clinic controls was 21.4% (95% confidence interval, −0.2%, 38.4%) for ≥2 PCV10 doses and among 3–11 month olds was 47.3% (10.5%, 69.0%) for three doses. aVE increased with higher numbers of doses in clinic control sets (p = 0.007). In contrast, aVE using community controls was 7.6% (95% confidence interval, −22.2%, 30.0%) for ≥2 doses. We found vaccine introduction in the study area faster and less variable than expected with 75% coverage on average, which reduced power. Information bias may also have affected community controls. Conclusions: Clinic control analyses show PCV10 prevented radiographic pneumonia in Bangladesh, especially among younger children receiving three doses. While both analyses were underpowered, community control enrollment – compared to clinic controls – was more difficult in a complex, pluralistic healthcare system. Future studies in comparable settings may consider alternative study designs.
AB - Background: Pneumococcal conjugate vaccine (PCV) effectiveness against radiographic pneumonia in South Asia is unknown. Bangladesh introduced PCV10 in 2015 using a three dose primary series (3 + 0). We sought to measure PCV10 effectiveness for two or more vaccine doses on radiographic pneumonia among vaccine-eligible children in rural Bangladesh. Methods: We conducted a matched case-control study over two years from 2015 to 2017 using clinic and community controls in three subdistricts of Sylhet, Bangladesh. Cases were vaccine eligible 3–35 month olds at Upazila Health Complex outpatient clinics with World Health Organization-defined radiographic primary endpoint pneumonia (radiographic pneumonia). Clinic controls were matched to cases within a one week time window by age, sex, and clinic and had an illness unlikely to be Streptococcus pneumoniae; community controls were healthy and similarly matched within a one week time window by age and sex, and distance from the clinic. We estimated adjusted vaccine effectiveness (aVE) using conditional logistic regression. Results: We matched 1262 cases with 2707 clinic and 2461 community controls. Overall, aVE using clinic controls was 21.4% (95% confidence interval, −0.2%, 38.4%) for ≥2 PCV10 doses and among 3–11 month olds was 47.3% (10.5%, 69.0%) for three doses. aVE increased with higher numbers of doses in clinic control sets (p = 0.007). In contrast, aVE using community controls was 7.6% (95% confidence interval, −22.2%, 30.0%) for ≥2 doses. We found vaccine introduction in the study area faster and less variable than expected with 75% coverage on average, which reduced power. Information bias may also have affected community controls. Conclusions: Clinic control analyses show PCV10 prevented radiographic pneumonia in Bangladesh, especially among younger children receiving three doses. While both analyses were underpowered, community control enrollment – compared to clinic controls – was more difficult in a complex, pluralistic healthcare system. Future studies in comparable settings may consider alternative study designs.
KW - Asia
KW - Bangladesh
KW - Child
KW - Infant
KW - Pneumococcal vaccines
KW - Radiography
KW - Respiratory tract infections
UR - http://www.scopus.com/inward/record.url?scp=85090066340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090066340&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2020.08.035
DO - 10.1016/j.vaccine.2020.08.035
M3 - Article
C2 - 32873404
AN - SCOPUS:85090066340
SN - 0264-410X
VL - 38
SP - 6508
EP - 6516
JO - Vaccine
JF - Vaccine
IS - 42
ER -